![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 16, 16088-16095, April 22, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


From the Laboratoire de génétique moléculaire, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec H2W 1R7, Canada
Gene inactivation studies have suggested that the product of the retinoblastoma gene, Rb, is particularly limiting in pituitary pro-opiomelanocortin (POMC)-expressing cell lineages. Indeed, in Rb knock-out mice, these cells develop tumors with high frequency. To understand the implication of limiting Rb expression in these cells, we investigated the action of Rb and its related pocket proteins, p107 and p130, on POMC gene transcription. This led to the identification of the neurogenic basic helix-loop-helix transcription factor, NeuroD1, as a target of Rb action. Rb and to a lesser extent p107, but not p130, enhance NeuroD1-dependent transcription, and this activity appears to depend on direct protein interactions between the Rb pocket and the helix-loop-helix domain of NeuroD1. In vivo, NeuroD is found in a complex that includes Rb and also the orphan nuclear receptor NGFI-B, which mediates corticotropin-releasing hormone activation of POMC transcription. The formation of a similar complex in vitro requires the presence of Rb as a bridge between NeuroD and NGFI-B. In POMC-expressing AtT-20 cells, Rb and p107 are present on the POMC promoter and inhibition of their expression through small interfering RNA decreases POMC mRNA levels. The action of Rb and its related proteins on POMC transcription may contribute to the establishment and/or maintenance of the differentiation phenotype.
Received for publication, November 29, 2004 , and in revised form, February 3, 2005.
* This work was supported by grants from the Canadian Institutes of Health Research and the National Cancer Institute of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received fellowships from the Association pour la recherche contre le cancer (ARC), the Cancer Research Society (CRS), and the La ligue contre le cancer.
To whom correspondence should be addressed: Laboratoire de gé-nétique moléculaire, Institut de recherches cliniques de Montréal (IRCM), 110, avenue des Pins Ouest, Montréal Québec H2W 1R7, Canada. Tel.: 514-987-5680; Fax: 514-987-5575; E-mail: jacques.drouin{at}ircm.qc.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P.-L. Lavoie, L. Budry, A. Balsalobre, and J. Drouin Developmental Dependence on NurRE and EboxNeuro for Expression of Pituitary Proopiomelanocortin Mol. Endocrinol., July 1, 2008; 22(7): 1647 - 1657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bilodeau, S. Vallette-Kasic, Y. Gauthier, D. Figarella-Branger, T. Brue, F. Berthelet, A. Lacroix, D. Batista, C. Stratakis, J. Hanson, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes & Dev., October 15, 2006; 20(20): 2871 - 2886. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. MacWilliams, K. Doquang, R. Pedrola, G. Dollman, D. Grassi, T. Peis, A. Tsang, and A. Ceccarelli A retinoblastoma ortholog controls stalk/spore preference in Dictyostelium Development, April 1, 2006; 133(7): 1287 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Batsche, J. Desroches, S. Bilodeau, Y. Gauthier, and J. Drouin Rb Enhances p160/SRC Coactivator-dependent Activity of Nuclear Receptors and Hormone Responsiveness J. Biol. Chem., May 20, 2005; 280(20): 19746 - 19756. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |